1-20 of 354 Search Results for

egfr

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Book
Book Chapter
Series: Advances in Oto-Rhino-Laryngology
Volume: 62
Published: 25 November 2004
10.1159/000082475
EISBN: 978-3-318-01119-7
... are of interest, including modulators of the epidermal growthfactor receptor (EGFR). Therefore we investigated whether the addition of monoclonalantibodies against the EGFR could enhance the response rate of cisplatin, 5-FU and docetaxel.Squamous cell cancer lines were transplanted into nude mice. After tumors...
Book Chapter
Series: Current Problems in Dermatology
Volume: 46
Published: 22 December 2014
10.1159/000367959
EISBN: 978-3-318-02763-1
... Abstract The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase. Its correct function is required for normal skin development and homeostasis, while dysregulation of EGFR signalling results in cellular hyper-proliferation and defects in differentiation, leading to impaired...
Book Chapter
Series: Progress in Tumor Research
Volume: 41
Published: 19 February 2014
10.1159/000355902
EISBN: 978-3-318-02542-2
...', for their proliferation and survival. EGFR (epidermal growth factor receptor) mutations and ALK (anaplastic lymphoma kinase) rearrangement are typical examples of such driver oncogenic mutations found in lung adenocarcinomas. EGFR-tyrosine kinase inhibitors (TKIs) or ALK-TKIs significantly improved treatment...
Book Chapter
Series: Progress in Tumor Research
Volume: 41
Published: 19 February 2014
EISBN: 978-3-318-02542-2
... label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128. 5. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388. 6. Rosell R, Carcereny E, Gervais R, Vergnenegre...
Book Chapter
Series: Current Problems in Dermatology
Volume: 53
Published: 13 November 2017
10.1159/000479198
EISBN: 978-3-318-06101-7
... ]. Papulopustular eruption appears in 50-100% of patients treated with epidermal growth factor receptor (EGFR) inhibitors (both monoclonal antibodies and tyrosine-kinase inhibitors). It can also be seen in 10-60% of patients treated with mammalian target of rapamycin inhibitors. The agents related...
Book Chapter
Series: Nestlé Nutrition Institute Workshop Series
Volume: 84
Published: 18 January 2016
10.1159/000436992
EISBN: 978-3-318-05599-3
... with activating epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) showed dramatic improvement in progression-free survival (PFS) when treated with EGFR-targeting erlotinib versus gemcitabine plus carboplatin in the OPTIMAL study (fig. 3 ) [ 5 ]. This result has...
Book Chapter
Series: Current Problems in Dermatology
Volume: 46
Published: 22 December 2014
EISBN: 978-3-318-02763-1
.... 5. Avraham R, Yarden Y: Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol 2011;12:104-117. 6. Nanney LB, Magid M, Stoscheck CM, King LE Jr: Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis...
Book Chapter
Series: Progress in Tumor Research
Volume: 41
Published: 19 February 2014
10.1159/000356436
EISBN: 978-3-318-02542-2
... Abstract Constant development of chemotherapy and more recently the introduction of VEGF- and epidermal growth factor receptor (EGFR)-directed agents have improved significantly the treatment of patients with colorectal cancer. In the adjuvant setting, especially for UICC stage III colon cancer...
Book Chapter
Series: Contributions to Nephrology
Volume: 192
Published: 08 February 2018
10.1159/000484284
EISBN: 978-3-318-06251-9
...% [ 4 ]. Importantly, the beneficial impact of RASB in patients with diabetes and established DN was only seen in those with estimated glomerular filtration rate (eGFRs) <60 mL/min/1.73 m 2 [ 3 ] and the extension of renal survival in those cases was generally less than 2 years. Thus, new treatment...
Book Chapter
Series: Frontiers of Radiation Therapy and Oncology
Volume: 42
Published: 07 December 2009
10.1159/000262457
EISBN: 978-3-8055-9299-4
... ]. Prognostic Implication of Molecular Markers A wide range of genetic and phenotypic abnormalities have been identified in lung cancer. However, only a few are known to have an impact on patient outcome and thus may influence choice of therapy: EGFR and K-RAS in Lung Cancer Mutations of genes...
Book Chapter
Series: Chemical Immunology and Allergy
Volume: 97
Published: 07 May 2012
10.1159/000335632
EISBN: 978-3-8055-9971-9
... dystrophies and stomatitis. Extravasation injuries or hypersensitivity reactions may be severe. New oncologic agents have led to the development of different, class-specific cutaneous side effects. Epidermal growth factor receptor (EGFR) inhibitors induce papulopustular rashes in a high percentage of patients...
Book Chapter
Series: Progress in Neurological Surgery
Volume: 34
Published: 28 May 2019
10.1159/000493057
EISBN: 978-3-318-06422-3
... therapy. Improved knowledge of tumor biology has led to the identification of specific molecular drivers of cancer development and progression. Of note, insertions and/or deletions within the EGFR gene and EML4-ALK chromosomal translocation in lung cancer, BRAF mutation in melanoma, as well...
Book Chapter
Series: Current Problems in Dermatology
Volume: 53
Published: 13 November 2017
EISBN: 978-3-318-06101-7
... Am Acad Dermatol 2007;56:317-326. 4. Osio A, Mateus C, Soria JC, Massard C, Malka D, Boige V, Besse B, Robert C: Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol 2009;161:515-521. 5. Lenz HJ: Anti-EGFR mechanism...
Book Chapter
Series: Contributions to Nephrology
Volume: 192
Published: 08 February 2018
10.1159/000484277
EISBN: 978-3-318-06251-9
... relationship between the levels of serum uric acid (SUA) and changes in estimated glomerular filtration rate (eGFR) was not clear, we observed that high SUA was associated with larger decrease in eGFR. People with hyperuricemia, >7.0 mg/dL, may have an unhealthy lifestyle. We observed to see if intensive...
Book Chapter
Series: Contributions to Nephrology
Volume: 199
Published: 17 December 2021
10.1159/000517710
EISBN: 978-3-318-06937-2
... and Kidney Disease: Scientific Background In 2013, Lue et al. [ 11 ] observed that patients living closer to a major roadway had a lower estimated glomerular filtration rate (eGFR) than patients living farther away in a cohort of 1,103 patients hospitalized with confirmed acute ischemic stroke...
Book
Book Cover Image
Series: Progress in Tumor Research
Volume: 41
Published: 19 February 2014
10.1159/isbn.978-3-318-02542-2
EISBN: 978-3-318-02542-2
Book Chapter
Series: Contributions to Nephrology
Volume: 181
Published: 13 May 2013
10.1159/000348636
EISBN: 978-3-318-02390-9
...' in the National Kidney Foundation Disease Outcomes Quality Initiative (NKF-KDOQI), the estimated glomerular filtration rate (eGFR) was calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula: 141 × min (serum creatinine (Scr)/κ, 1) α × max (Scr/κ, 1) -1.209 × 0.993 Age × 1.018...
Book Chapter
Series: Frontiers in Diabetes
Volume: 27
Published: 18 June 2019
10.1159/000486265
EISBN: 978-3-318-06507-7
... by the presence of markers of renal damage, most commonly, albuminuria and/or decline in kidney function assessed by estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m 2 ) for ≥3 months. Albuminuria is classified by rate of excretion into microalbuminuria (urinary albumin: creatinine ratio [ACR...
Book Chapter
Series: Progress in Neurological Surgery
Volume: 32
Published: 23 July 2018
10.1159/000469681
EISBN: 978-3-318-06063-8
... transition factor, also known as hepatocyte growth factor receptor [ HGFR ]; located at 7q31). The classical subtype was characterized by high-level amplification of EGFR (epidermal growth factor receptor; located at 7p12), expression of mutant EGFR variant III ( EGFRvIII ), lack of TP53 mutations...